HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The molecular mechanism of fetal hemoglobin reactivation.

Abstract
Increased levels of fetal hemoglobin (HbF) are clinically beneficial in patients with sickle cell disease. Hydroxurea fails to increase HbF in at least 25% of patients, and therefore, better drugs are needed. Recent clinical studies have shown that the DNA methyltransferase (DNMT) inhibitor decitabine effectively increased HbF in hydroxyurea-refractory patients. The rational use of DNMT inhibitors as therapeutic agents to reactivate HbF expression in patients with sickle cell disease is based on nearly 25 years of experimental evidence, reviewed in this article, that supports a fundamental role of DNA methylation in the silencing of gamma-globin gene expression in adults.
AuthorsDonald E Lavelle
JournalSeminars in hematology (Semin Hematol) Vol. 41 Issue 4 Suppl 6 Pg. 3-10 (Oct 2004) ISSN: 0037-1963 [Print] United States
PMID15534851 (Publication Type: Journal Article, Review)
Chemical References
  • Fetal Hemoglobin
Topics
  • Animals
  • CpG Islands
  • DNA Methylation
  • Fetal Hemoglobin (genetics)
  • Gene Silencing
  • Humans
  • Promoter Regions, Genetic (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: